Transcribed

Personal journeys and hard-earned lessons behind biotech’s biggest breakthroughs

Featured interview

with Jacob Berlin

Cofounder and CEO
Terray Therapeutics

Small molecules make up most drug approvals but still have a 1% discovery success rate. Jacob Berlin on how Terray built a dataset 40x larger than the entire public chemistry set and why the future of small-molecule drug discovery is agentic.

View now

Podcast available on

More stories

Watch

Kate Haviland on strategic pivots and turning a phase 3 failure into a blockbuster

Watch

Janice Chen on the CRISPR endgame and why the biggest barrier isn’t scientific

Watch

Nicole Paulk on radical ideas and the quest for a universal gene therapy

Watch

Gleb Kuznetsov on breaking the in vivo bottleneck and building a true platform company

Read

Eric Kelsic on breaking with convention and how Dyno Therapeutics is solving the gene delivery prob…

Listen

Andrew Bellinger on contrarian bets — and pioneering gene editing at Verve

Transcribed